Literature DB >> 26042237

Immunotherapy: The path to win the war on cancer?

Suzanne L Topalian, Jedd D Wolchok, Timothy A Chan, Ira Mellman, Karolina Palucka, Jacques Banchereau, Steven A Rosenberg, K Dane Wittrup.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26042237      PMCID： PMC6369529          DOI： 10.1016/j.cell.2015.03.045

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


× No keyword cloud information.
  46 in total

1.  CD137-CRDI is not necessary in the role of contacting its natural ligand.

Authors:  Ling Yi; Zhuohong Yan; Hongyan Jia; Xiaojue Wang; Yanlin Zhao; Hongtao Zhang
Journal:  Immunol Cell Biol       Date:  2016-08-16       Impact factor: 5.126

2.  Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy.

Authors:  Alberto Purwada; Ye F Tian; Weishan Huang; Kathleen M Rohrbach; Simrita Deol; Avery August; Ankur Singh
Journal:  Adv Healthc Mater       Date:  2016-04-21       Impact factor: 9.933

3.  Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ.

Authors:  Chang Liu; Maria Chikina; Rahul Deshpande; Ashley V Menk; Ting Wang; Tracy Tabib; Erin A Brunazzi; Kate M Vignali; Ming Sun; Donna B Stolz; Robert A Lafyatis; Wei Chen; Greg M Delgoffe; Creg J Workman; Stacy G Wendell; Dario A A Vignali
Journal:  Immunity       Date:  2019-07-23       Impact factor: 31.745

Review 4.  T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.

Authors:  David Schrama; Cathrin Ritter; Jürgen C Becker
Journal:  Semin Immunopathol       Date:  2017-01-10       Impact factor: 9.623

5.  PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  S Klein; D Ghersi; M P Manns; I Prinz; M Cornberg; A R M Kraft
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

Review 6.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 7.  Kras and Tumor Immunity: Friend or Foe?

Authors:  Jane Cullis; Shipra Das; Dafna Bar-Sagi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

8.  ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance.

Authors:  Joseph R Podojil; Iris Hecht; Ming-Yi Chiang; Ilan Vaknin; Inbal Barbiro; Amit Novik; Eyal Neria; Galit Rotman; Stephen D Miller
Journal:  J Immunol       Date:  2018-02-05       Impact factor: 5.422

Review 9.  Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.

Authors:  Amblessed E Onuma; Hongji Zhang; Hai Huang; Terence M Williams; Anne Noonan; Allan Tsung
Journal:  Gene Expr       Date:  2020-04-27

Review 10.  Targeted therapies for renal cell carcinoma.

Authors:  Edwin M Posadas; Suwicha Limvorasak; Robert A Figlin
Journal:  Nat Rev Nephrol       Date:  2017-07-10       Impact factor: 28.314
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.